Desvenlafaxine Tablet, Film Coated, Extended Release
Product Images NDC 50090-4806

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 50090-4806). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chem-structure.jpg (Chem Structure)

FDA Label Image

Figure1.jpg (Figure1)

This appears to be a chart or table with information related to renal impairment, hepatic impairment, and PK (probably pharmacokinetics) for different populations based on gender and age. The table includes information on mild, moderate, and severe impairment for both renal and hepatic function, as well as end-stage renal disease (ESRD). The PK section includes details on the geometric mean ratio for parameters such as Cmax and AUC, with some data missing. Overall, this table provides information that could be useful for healthcare professionals in determining dosages or treatment plans for patients with impaired renal or hepatic function.*

FDA Label Image

Figure2.jpg (Figure2)

This text shows the change in CYP3A4 inhibitors due to PK, specifically with regards to Ketoconazole Cmax. It provides information on geometric mean ratios with associated confidence intervals. However, the context and significance of this information is not clear and may require additional information in order to be useful.*

FDA Label Image

Figure3.jpg (Figure3)

FDA Label Image

Figure4.jpg (Figure4)

FDA Label Image

Figure5.jpg (Figure5)

FDA Label Image

Label Image (Lbl500904806)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.